Yeo E, et al. - Three secular cohorts of 216 adults who received dialysis for at least 90 days on February 1, 2017, January 1, 2016, and January 1, 2015, were recognized by experts in order to determine the point prevalence of gout (the most common form of inflammatory arthritis in adults), gout treatment and achievement of target serum urate (SU) among adults treated with long-term dialysis. Outcomes were contrasted among hemodialysis (HD) and peritoneal dialysis (PD), and subjects prescribed and not prescribed urate-lowering therapy. Sixty-one out of 216 had a gout diagnosis. Among those with gout, the mean age was 61 years out of which 46 were men and 18 recognized as Māori or Pacific Island. Allopurinol was prescribed to 42. A predialysis SU ≤0.36 mmol/L was found in 46% of the individuals on less than 25% of occasions and 23% were below target on 76–100% of events. With no statistically meaningful variation in those on HD or PD, and those prescribed or not prescribed allopurinol, SU was below target 41% of the time. Hence, gout was encountered by approximately one in four adults who were treated with dialysis and two-thirds are prescribed allopurinol. Moreover, a minority had SU at a target adequate to prevent gout regardless of allopurinol and HD. Further, in those with SU above the target, a treat to target SU should be acknowledged.